Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study.

Penfornis A, Bourdel-Marchasson I, Quere S, Dejager S.

Diabetes Metab. 2012 Dec;38(6):550-7. doi: 10.1016/j.diabet.2012.08.003. Epub 2012 Sep 18.

PMID:
22996038
[PubMed - indexed for MEDLINE]
Free Article
2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
3.

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.

Bosi E, Dotta F, Jia Y, Goodman M.

Diabetes Obes Metab. 2009 May;11(5):506-15. doi: 10.1111/j.1463-1326.2009.01040.x. Epub 2009 Mar 23.

PMID:
19320662
[PubMed - indexed for MEDLINE]
4.

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.

Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 Investigators.

Int J Clin Pract. 2010 Nov;64(12):1619-31. doi: 10.1111/j.1742-1241.2010.02510.x. Epub 2010 Sep 16.

PMID:
20846286
[PubMed - indexed for MEDLINE]
5.

Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.

Schwarz SL, Gerich JE, Marcellari A, Jean-Louis L, Purkayastha D, Baron MA.

Diabetes Obes Metab. 2008 Aug;10(8):652-60. Epub 2007 Oct 15.

PMID:
17941876
[PubMed - indexed for MEDLINE]
6.

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.

Diabetes Obes Metab. 2009 Feb;11(2):157-66. doi: 10.1111/j.1463-1326.2008.00994.x. Erratum in: Diabetes Obes Metab. 2009 Apr;11(4):405.

PMID:
19125777
[PubMed - indexed for MEDLINE]
7.

Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.

Gitt AK, Bramlage P, Binz C, Krekler M, Deeg E, Tschöpe D.

Int J Clin Pract. 2013 Oct;67(10):1005-14. doi: 10.1111/ijcp.12179. Epub 2013 Aug 28.

PMID:
23981060
[PubMed - indexed for MEDLINE]
8.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
[PubMed - indexed for MEDLINE]
9.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.

Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.

PMID:
17593236
[PubMed - indexed for MEDLINE]
10.

Relationship between HbA1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin.

Chan JY, Leyk M, Frier BM, Tan MH.

Diabetes Metab Res Rev. 2009 Mar;25(3):224-31. doi: 10.1002/dmrr.929.

PMID:
19156705
[PubMed - indexed for MEDLINE]
11.

Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.

Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P; IMPROVE Study Group Expert Panel.

Curr Med Res Opin. 2009 Nov;25(11):2643-54. doi: 10.1185/03007990903276745.

PMID:
19751116
[PubMed - indexed for MEDLINE]
12.

Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.

Hassanein M, Hanif W, Malik W, Kamal A, Geransar P, Lister N, Andrews C, Barnett A.

Curr Med Res Opin. 2011 Jul;27(7):1367-74. doi: 10.1185/03007995.2011.579951. Epub 2011 May 16.

PMID:
21568833
[PubMed - indexed for MEDLINE]
13.
14.

Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.

Kvapil M, Swatko A, Hilberg C, Shestakova M.

Diabetes Obes Metab. 2006 Jan;8(1):39-48.

PMID:
16367881
[PubMed - indexed for MEDLINE]
15.

The management of people with type 2 diabetes with hypoglycaemic agents in primary care: retrospective cohort study.

Calvert MJ, McManus RJ, Freemantle N.

Fam Pract. 2007 Jun;24(3):224-9. Epub 2007 May 7.

PMID:
17488736
[PubMed - indexed for MEDLINE]
Free Article
16.

Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.

Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF.

Curr Med Res Opin. 2009 Mar;25(3):607-15. doi: 10.1185/03007990802711024 .

PMID:
19232035
[PubMed - indexed for MEDLINE]
17.

Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.

Krobot KJ, Ferrante SA, Davies MJ, Seck T, Meininger GE, Williams-Herman D, Kaufman KD, Goldstein BJ.

Curr Med Res Opin. 2012 Aug;28(8):1281-7. doi: 10.1185/03007995.2012.703134. Epub 2012 Jul 6.

PMID:
22697277
[PubMed - indexed for MEDLINE]
19.

A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.

Violante R, Oliveira JH, Yoon KH, Reed VA, Yu MB, Bachmann OP, Lüdemann J, Chan JY.

Diabet Med. 2012 Nov;29(11):e417-24. doi: 10.1111/j.1464-5491.2012.03624.x.

PMID:
22375612
[PubMed - indexed for MEDLINE]
20.

Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.

Chwieduk CM.

Drugs. 2011 Feb 12;71(3):349-61. doi: 10.2165/11206060-000000000-00000. Review.

PMID:
21319871
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk